|
|
| Yang,R.F.; Yu,B.; Zhang,R.Q.; Wang,X.H.; Li,C.; Wang,P.; Zhang,Y.; Han,B.; Gao,X.X.; Zhang,L.; Jiang,Z.M.. |
| Non-small-cell lung cancer (NSCLC) patients who experience brain metastases are usually associated with poor prognostic outcomes. This retrospective study proposed to assess whether bevacizumab or gefitinib can be used to improve the effectiveness of whole brain radiotherapy (WBRT) in managing patients with brain metastases. A total of 218 NSCLC patients with multiple brain metastases were retrospectively included in this study and were randomly allocated to bevacizumab-gefitinib-WBRT group (n=76), gefitinib-WBRT group (n=77) and WBRT group (n=75). Then, tumor responses were evaluated every 2 months based on Response Evaluation Criteria in Solid Tumors version 1.0. Karnofsky performance status and neurologic examination were documented every 6 months after... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Non-small-cell lung cancer; Brain metastasis; Bevacizumab; Gefitinib; Whole brain radiotherapy. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000100606 |
| |
